Table 1 Baseline clinical and cardiovascular magnetic resonance (CMR) characteristics
From: Myocardial extracellular volume by T1 mapping: a new marker of arrhythmia in mitral valve prolapse
|  | MVP–MAD n = 30 | Control group (No MVP) | |||
|---|---|---|---|---|---|
MR-NoMAD n = 14 | P vs MVP–MAD | NoMR-NoMAD n = 10 | P vs MVP–MAD | ||
Age (y) | 50 ± 17 | 53 ± 22 | 0.70 | 46 ± 21 | 0.53 |
Male, n (%) | 18 (60%) | 7 (50%) | 0.75 | 6 (60%) | 1.0 |
Weight (kg) | 72 ± 12 | 70 ± 14 | 0.69 | 82 ± 13 | 0.02 |
Height (cm) | 177 ± 10 | 170 ± 10 | 0.04 | 179 ± 11 | 0.65 |
Hypertension, n (%) | 2 (7%) | 6 (43%) | 0.008 | 2 (20%) | 0.26 |
Active smoker, n (%) | 3 (10%) | 1 (7%) | 1.0 | 1 (10%) | 1.0 |
Hyperlipidaemia, n (%) | 2 (7%) | 2 (14%) | 0.58 | 2 (20%) | 0.26 |
LVEDV (ml) | 192 ± 56 | 148 ± 39 | 0.01 | 164 ± 29 | 0.14 |
LVEDVI (ml/m2) | 102 ± 29 | 81 ± 17 | 0.018 | 82 ± 16 | 0.048 |
LVESV (ml) | 84 ± 32 | 60 ± 21 | 0.02 | 70 ± 12 | 0.20 |
LVEF (%) | 57 ± 8 | 60 ± 8 | 0.32 | 57 ± 3 | 0.99 |
LV mass index (g/m2) | 66 ± 16 | 62 ± 15 | 0.45 | 63 ± 9 | 0.59 |
MAD length (mm) | 9.4 [7.1–12.3] | – |  | – |  |
Presence of LGE, n (%) | 14 (47%) | 0 (0%) | 0.002 | 0 (0%) | 0.007 |
 N of positive segments (n = 14) | 3 [3–4] | 0 |  | 0 |  |
Basal slice pre-Gd T1 (ms) | 1067 ± 45 | 1029 ± 37 | 0.009 | 1029 ± 26 | 0.016 |
Basal slice ECVsyn (%) | 30 ± 3 | 24 ± 3 | < 0.0001 | 24 ± 2 | < 0.0001 |